{"entity":{"id":"ono-pharmaceutical","kind":"company","name":"Ono Pharmaceutical","aka":["ONO PHARMACEUTICAL CO., LTD.","Ono Pharma"],"tldr":"Ono Pharmaceutical is an Osaka drug company that launched the immunotherapy nivolumab (Opdivo) in Japan in 2014. It bought the US company Deciphera Pharmaceuticals in 2024.","summary":"Ono Pharmaceutical Co., Ltd. traces its origins to an apothecary opened in Doshomachi, Osaka, in 1717; the present company was established in 1947 and listed on the Osaka Securities Exchange in 1962 and the Tokyo Stock Exchange in 1963. Its headquarters are in Chuo, Osaka. In 2014 it launched OPDIVO, which its history describes as the world's first anti-PD-1 antibody, in Japan. In 2024 it acquired Deciphera Pharmaceuticals, a US company whose medicines include ripretinib.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.ono-pharma.com/en"},{"label":"Ono Pharmaceutical: history","url":"https://www.ono-pharma.com/en/company/history"},{"label":"Ono Pharmaceutical: head offices","url":"https://www.ono-pharma.com/en/company/about/office"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","targeted-therapy"],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Facts are from Ono's own history and office pages, read on 3 November 2026. The stock code was not shown on the pages that loaded and is omitted. Nivolumab is linked because Ono's history records launching Opdivo; its partnership terms with Bristol Myers Squibb were not read for this record. Ripretinib is named as a Deciphera medicine per the deal map and the Deciphera record, not Ono's pages."],"hq":"Osaka","country":"JP","companyType":"pharma","website":"https://www.ono-pharma.com/en","founded":1947,"stage":"public","investors":[],"funding":[]},"route":"/companies/ono-pharmaceutical/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}]}}